Skip to content
value.today

Gilgamesh Pharma Inc.

🇺🇸 New York, New York, USAPharmaceuticalsFounded 2025
Total raised
$68 M
3 rounds on record
Latest round
$2 M
Mar 2026
First round on record
Jan 2026
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Gilgamesh Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$2 MNo. 3$2 to $10 million

Gilgamesh Pharma Inc.: Raise no. 3, Mar 2026

Investors in this round

3 investors had bought by the notice of Mar 31, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $15 M offered; $13 M still to sell
Smallest investment taken
$50,000
What was sold
options or other rights to buy securities, other: Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may conve
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Kruegel · Executive Officer, Director
  • Jonathan Sporn · Executive Officer, Director
  • Amy Kruse · Director
  • Phil Skolnick · Director
  • Robert Berman · Director
  • Zia Huque · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Sporn, Ceo. Source: SEC Form D, newest notice filed Mar 31, 2026. Read the notice at the SEC.

optionsSEC
Mar 2026$60 MNo. 2$50 to $250 million

Gilgamesh Pharma Inc.: Raise no. 2, Mar 2026

Investors in this round

40 investors had bought by the notice of Mar 24, 2026: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
$50,000
What was sold
equity, other: Shares of Preferred Stock of Issuer and the shares of capital stock of Issuer into which such shares of Preferred Stock may convert.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Kruegel · Executive Officer, Director
  • Jonathan Sporn · Executive Officer, Director
  • Amy Kruse · Director
  • Phil Skolnick · Director
  • Robert Berman · Director
  • Zia Huque · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Sporn, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 24, 2026. Read the notice at the SEC.

equitySEC
Jan 2026$6 MNo. 1$2 to $10 million

Gilgamesh Pharma Inc.: Raise no. 1, Jan 2026

Investors in this round

9 investors had bought by the notice of Feb 4, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
$27,597
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Kruegel · Executive Officer, Director
  • Jonathan Sporn · Executive Officer, Director
  • Amy Kruse · Director
  • Phil Skolnick · Director
  • Robert Berman · Director
  • Zia Huque · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Sporn, Ceo. Source: SEC Form D, newest notice filed Feb 4, 2026. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Gilgamesh Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).

    SEC Form D · Mar 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2026

That is all the official record says: Gilgamesh Pharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Gilgamesh Pharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 40 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Gilgamesh Pharma Inc.
NameRoleNamed in
Andrew KruegelExecutive officerMar 2026
Jonathan SpornExecutive officerMar 2026
Amy KruseDirectorMar 2026
Andrew KruegelDirectorMar 2026
Jonathan SpornDirectorMar 2026
Phil SkolnickDirectorMar 2026
Robert BermanDirectorMar 2026
Zia HuqueDirectorMar 2026